Phase II MCL-001 (EMERGE) Study of Single-Agent Lenalidomide in Relapsed/Refractory MCL


Phase II MCL-001 (EMERGE) Study of Single-Agent Lenalidomide in Relapsed/Refractory MCL
Slides from a presentation at EHA 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (10/26/13)
Goy A et al. Single-agent lenalidomide in patients with relapsed/refractory mantle cell lymphoma following bortezomib: Efficacy, safety and pharmacokinetics from the multicenter Phase II MCL-001 “EMERGE” trial. Proc EHA 2013;Abstract S1156.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts University School of Medicine and Director of the Lymphoma Program and Leader of the Clinical Sciences Program at Tufts Cancer Center in Boston, Massachusetts.